Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials

References

• Thase ME. Update on partial response in depression. J Clin Psychiatry 2009;70(Suppl 6):4-9
   PubMedGoogle Scholar
• Katz MM, Frazer A, Bowden CL. ‘Delay’ hypothesis of onset of antidepressant action. Br J Psychiatry 2006;188:586-7
   PubMed Web of Science ®Google Scholar
• Rojo JE, Gibert K, Cobo J, et al. Onset of antidepressant action: a pharmacological question? Hum Psychopharmacol 2005;20:425-33
   PubMed Web of Science ®Google Scholar
• Taylor MJ. Rapid onset of true antidepressant action. Curr Psychiatry Rep 2007;9:475-9
   PubMedGoogle Scholar
• Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63:1217-23
   PubMed Web of Science ®Google Scholar
• Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006;22:2101-10
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26:56-60
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009;24:111-18
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26:56-60
   PubMed Web of Science ®Google Scholar
• Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009;70:344-53
   PubMed Web of Science ®Google Scholar
• Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol 2012;22(Suppl 3):S492-8
   PubMed Web of Science ®Google Scholar
• Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 2009;15:107-17
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57
   PubMed Web of Science ®Google Scholar
• Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
   PubMed Web of Science ®Google Scholar
• Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008;69(Suppl E1):4-7
   PubMed Web of Science ®Google Scholar
• Portella MJ, de Diego-Adelino J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011;72:962-9
   PubMed Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Sussman N. Depression and painful physical symptoms. Primary care companion to the Journal of Clinical Psychiatry 2003;5(Suppl 7):19-26
   PubMedGoogle Scholar
• Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep 2011;13:476-82
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004;24:507-11
   PubMed Web of Science ®Google Scholar
• Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007;68:1195-205
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 2009;24:269-75
   PubMed Web of Science ®Google Scholar
• Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010;6:23-31
   PubMed Web of Science ®Google Scholar
• Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry 2009;70:1069-77
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectrums 2009;14:326-33
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacoly 2004;19:149-55
   PubMed Web of Science ®Google Scholar